LT4374873T - Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai - Google Patents

Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai

Info

Publication number
LT4374873T
LT4374873T LTEP24164640.5T LT24164640T LT4374873T LT 4374873 T LT4374873 T LT 4374873T LT 24164640 T LT24164640 T LT 24164640T LT 4374873 T LT4374873 T LT 4374873T
Authority
LT
Lithuania
Prior art keywords
treating
preventing
agent
opthalmological
conditions
Prior art date
Application number
LTEP24164640.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Samir Patel
Original Assignee
Astellas Us Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Us Llc filed Critical Astellas Us Llc
Publication of LT4374873T publication Critical patent/LT4374873T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
LTEP24164640.5T 2013-07-12 2014-07-11 Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai LT4374873T (lt)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201361845936P 2013-07-12 2013-07-12
US201361845938P 2013-07-12 2013-07-12
US201361845935P 2013-07-12 2013-07-12
US201361866503P 2013-08-15 2013-08-15
US201361866507P 2013-08-15 2013-08-15
US201361866502P 2013-08-15 2013-08-15
US201361911860P 2013-12-04 2013-12-04
US201361911854P 2013-12-04 2013-12-04
US201361911894P 2013-12-04 2013-12-04
US201461926812P 2014-01-13 2014-01-13
US201461926825P 2014-01-13 2014-01-13
US201461926848P 2014-01-13 2014-01-13
US201461931116P 2014-01-24 2014-01-24
US201461931135P 2014-01-24 2014-01-24
US201461931125P 2014-01-24 2014-01-24

Publications (1)

Publication Number Publication Date
LT4374873T true LT4374873T (lt) 2025-12-29

Family

ID=52277261

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP24164640.5T LT4374873T (lt) 2013-07-12 2014-07-11 Agentas, skirtas panaudoti oftalmologinių būklių gydymui ir profilaktikai

Country Status (25)

Country Link
US (8) US20150017163A1 (enExample)
EP (3) EP3628373A1 (enExample)
JP (6) JP2016531901A (enExample)
KR (4) KR20220061248A (enExample)
CN (2) CN110193009A (enExample)
AU (5) AU2014286996A1 (enExample)
BR (1) BR112016000546A2 (enExample)
CA (2) CA2915255A1 (enExample)
CL (1) CL2016000055A1 (enExample)
DK (1) DK4374873T3 (enExample)
EA (1) EA201690212A8 (enExample)
ES (1) ES3058378T3 (enExample)
FI (1) FI4374873T3 (enExample)
HK (1) HK1223319A1 (enExample)
HR (1) HRP20251412T1 (enExample)
IL (4) IL326624A (enExample)
LT (1) LT4374873T (enExample)
MX (1) MX2016000364A (enExample)
MY (1) MY199027A (enExample)
PH (1) PH12015502773A1 (enExample)
PL (1) PL4374873T3 (enExample)
PT (1) PT4374873T (enExample)
SG (3) SG11201510315TA (enExample)
SI (1) SI4374873T1 (enExample)
WO (1) WO2015006734A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
SI4374873T1 (sl) 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
SI3215530T1 (sl) 2014-11-07 2020-02-28 Sesen Bio, Inc. Izboljšana protitelesa IL-6
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
KR20210157427A (ko) * 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
CN117531025A (zh) * 2016-06-16 2024-02-09 阿德夫拉姆生物技术股份有限公司 使用aav2变体和阿柏西普治疗amd
CN109937034B (zh) * 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
CN110650624A (zh) * 2017-03-10 2020-01-03 威斯康星州医药大学股份有限公司 用于视网膜疾病的核糖开关调节的基因治疗
WO2019040397A1 (en) * 2017-08-21 2019-02-28 Ophthotech Corporation METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE
AU2018370135A1 (en) * 2017-11-16 2020-06-04 Iveric Bio, Inc. A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
KR20200093621A (ko) * 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2020041689A1 (en) * 2018-08-23 2020-02-27 Bernstein Eric F Systems, devices and methods for applying anti-vegf compounds and using such compounds to treat skin conditions
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021046245A1 (en) * 2019-09-04 2021-03-11 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
AU2020345174A1 (en) * 2019-09-12 2022-03-31 Lupin Limited Modified dosing of VEGF inhibitors for ophthalmic use
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
US20230340529A1 (en) * 2020-09-03 2023-10-26 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
CA3197023A1 (en) * 2020-11-01 2022-05-05 Iveric Bio, Inc. Methods for treating ophthalmological conditions
CN117015385A (zh) * 2020-11-01 2023-11-07 伊维希比奥公司 治疗眼科疾患的方法
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
JP2025522748A (ja) * 2022-06-30 2025-07-17 アステラス ユーエス エルエルシー 眼科状態を治療するための持続放出シリカヒドロゲル複合体およびそれを使用する方法
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601704A (en) 1983-10-27 1986-07-22 Abbott Laboratories Container mixing system with externally mounted drug container
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5731144A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5837834A (en) 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5811533A (en) 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
US6410322B1 (en) 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
US5731294A (en) 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995016032A1 (en) 1993-12-09 1995-06-15 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US6448077B1 (en) 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5859228A (en) 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5723594A (en) 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
ES2276405T3 (es) 1995-06-02 2007-06-16 Gilead Sciences, Inc. Ligandos de oligonucleotidos de alta afinidad a pdgf.
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69735292T2 (de) 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20070059302A1 (en) 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
WO2000023074A1 (en) 1998-10-22 2000-04-27 Binex Co., Ltd. Pharmaceutical composition containing decursin
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
PT1140175E (pt) 1998-12-21 2006-06-30 Ludwig Inst Cancer Res Anticorpos para o vegf-d truncado e suas utilizacoes
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6382219B1 (en) 1999-06-08 2002-05-07 Jeffery A. Jelten Tooth flossing device
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
DE29915878U1 (de) 1999-09-09 2000-10-26 Disetronic Licensing Ag, Burgdorf Vorrichtung zur Umfüllung von Arzneimitteln und Kanülenanordnung
US7078390B1 (en) 1999-10-15 2006-07-18 Gentier Biosystems Incorporation Ribozymes to growth factor originating in human platelet
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003528632A (ja) 2000-03-31 2003-09-30 インスティティ・パスツール 血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
AU2001263251A1 (en) 2000-05-17 2001-11-26 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to pdgf
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
US6585691B1 (en) 2001-05-11 2003-07-01 Jonathan J. Vitello Tamper evident end cap assembly for a loaded syringe and process
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2005512962A (ja) 2001-09-20 2005-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｐｄｇｆ抗体および設計抗体の産生方法
HRP20040406A2 (en) 2001-11-09 2005-02-28 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
EP1552002A4 (en) 2002-06-18 2006-02-08 Archemix Corp APTAMER TOXIN MOLECULES AND METHOD FOR THEIR USE
US20040249130A1 (en) 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US20070184089A1 (en) 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
US8828373B2 (en) 2002-11-20 2014-09-09 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US20090053138A1 (en) 2002-11-21 2009-02-26 Preiss Jeffrey R Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
WO2006050498A2 (en) 2004-11-02 2006-05-11 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20040253243A1 (en) 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US8039443B2 (en) 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050124565A1 (en) 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AU2003294437A1 (en) 2002-11-21 2004-06-18 Archemix Corporation Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
WO2004050899A2 (en) 2002-12-03 2004-06-17 Archemix Corporation Method for in vitro selection of 2’-substituted nucleic acids
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006516288A (ja) * 2003-01-21 2006-06-29 アーケミックス コーポレイション 眼の薬物療法において有用なアプタマー治療薬
WO2004073551A2 (en) 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
EP1620547B1 (en) 2003-04-21 2014-06-18 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2530349A1 (en) 2003-06-27 2005-01-06 Dnavec Research Inc. Method for transplanting lymphohematopoietic cells into mammal
CL2004001996A1 (es) 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CN1980947B (zh) 2004-04-22 2013-01-30 雷加多生物科学公司 改良的凝血因子调节物
US20050244462A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244500A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
ES2381014T3 (es) 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP1853298A2 (en) 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
US20090075342A1 (en) 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US7303041B2 (en) 2005-08-22 2007-12-04 Key Safety Systems, Inc. Vehicle soft impact detection
WO2007035621A1 (en) 2005-09-16 2007-03-29 (Osi) Eyetech, Inc. Ophthalmic syringe
US20080076742A1 (en) 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
DK2500030T4 (en) 2005-11-04 2018-10-29 Genentech Inc Use of complement pathway inhibitors for the treatment of eye diseases
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
ZA200807620B (en) * 2006-03-08 2009-12-30 Archemix Corp Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
JP2009540011A (ja) 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US7632244B2 (en) 2006-08-10 2009-12-15 Comar, Inc. Tamper evident tip cap assembly
CA2670944A1 (en) 2006-12-18 2008-06-26 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
WO2008153997A1 (en) 2007-06-07 2008-12-18 Brookwood Pharmaceuticals, Inc. Reduced-mass, long-acting dosage forms
KR20180005753A (ko) 2008-06-25 2018-01-16 에스바테크 - 어 노바티스 컴파니 엘엘씨 Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
JP2012525415A (ja) * 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
RU2567639C2 (ru) * 2009-06-17 2015-11-10 АббВай Биотерапеутикс Инк., Антитела против vegf и их применения
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
EP2563395A4 (en) 2010-04-30 2013-11-27 Lpath Inc TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8353869B2 (en) 2010-11-02 2013-01-15 Baxa Corporation Anti-tampering apparatus and method for drug delivery devices
SG10201703249PA (en) * 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
CA2868096C (en) 2012-03-28 2019-12-31 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
JP2015519373A (ja) * 2012-06-01 2015-07-09 オプソテック コーポレイションＯｐｈｔｈｏｔｅｃｈ Ｃｏｒｐｏｒａｔｉｏｎ 抗ｐｄｇｆアプタマーおよびｖｅｇｆ拮抗薬を含む組成物
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
SI4374873T1 (sl) * 2013-07-12 2026-01-30 Astellas Us Llc Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
WO2016025313A1 (en) 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
WO2019040397A1 (en) 2017-08-21 2019-02-28 Ophthotech Corporation METHOD FOR TREATING OR PREVENTING MACULAR DEGENERATION OF THE NEOVASCULAR AGE

Also Published As

Publication number Publication date
US20160296550A1 (en) 2016-10-13
BR112016000546A2 (pt) 2017-11-21
AU2024200948A1 (en) 2024-03-07
AU2022201404A1 (en) 2022-03-24
JP2018168175A (ja) 2018-11-01
IL278018A (en) 2020-11-30
KR102948178B1 (ko) 2026-04-10
KR20230152151A (ko) 2023-11-02
AU2022201404B2 (en) 2023-11-16
EP3019243A4 (en) 2017-03-15
EP4374873A2 (en) 2024-05-29
CN110193009A (zh) 2019-09-03
IL294463B2 (en) 2026-07-01
CA2915255A1 (en) 2015-01-15
US20220175813A1 (en) 2022-06-09
US12016875B2 (en) 2024-06-25
US20210369757A1 (en) 2021-12-02
EA201690212A8 (ru) 2016-08-31
US20230364122A1 (en) 2023-11-16
WO2015006734A1 (en) 2015-01-15
KR20220061248A (ko) 2022-05-12
IL294463A (en) 2022-09-01
JP2022153570A (ja) 2022-10-12
ES3058378T3 (es) 2026-03-10
JP2020158533A (ja) 2020-10-01
US11273171B2 (en) 2022-03-15
EP4374873B1 (en) 2025-10-22
JP2024075637A (ja) 2024-06-04
US20190381087A1 (en) 2019-12-19
KR20260047660A (ko) 2026-04-08
FI4374873T3 (fi) 2025-12-04
EP3019243A1 (en) 2016-05-18
DK4374873T3 (da) 2025-11-03
US11491176B2 (en) 2022-11-08
AU2020201824A1 (en) 2020-04-02
PL4374873T3 (pl) 2026-03-23
PH12015502773A1 (en) 2016-03-21
US20230364123A1 (en) 2023-11-16
AU2014286996A1 (en) 2016-01-07
HRP20251412T1 (hr) 2026-02-13
SI4374873T1 (sl) 2026-01-30
MX2016000364A (es) 2016-05-09
SG10201708882TA (en) 2017-12-28
JP7457068B2 (ja) 2024-03-27
CA3107182A1 (en) 2015-01-15
PT4374873T (pt) 2026-01-12
US20150017163A1 (en) 2015-01-15
CL2016000055A1 (es) 2016-10-07
HK1223319A1 (zh) 2017-07-28
AU2024200948B2 (en) 2025-09-11
EP3628373A1 (en) 2020-04-01
SG10201912985RA (en) 2020-02-27
JP2016531901A (ja) 2016-10-13
IL294463B1 (en) 2026-03-01
CN105431204A (zh) 2016-03-23
AU2025271125A1 (en) 2025-12-18
US20250000889A1 (en) 2025-01-02
EP4374873A3 (en) 2024-08-07
SG11201510315TA (en) 2016-01-28
JP2026090361A (ja) 2026-06-02
IL243485A0 (en) 2016-02-29
KR20160030396A (ko) 2016-03-17
MY199027A (en) 2023-10-10
IL326624A (en) 2026-04-01
EA201690212A1 (ru) 2016-06-30

Similar Documents

Publication Publication Date Title
SI4374873T1 (sl) Sredstvo za uporabo pri zdravljenju ali preprečevanju oftalmoloških stanj
SG11201507507PA (en) Compositions and methods for treating mpsi
PT2991600T (pt) Micro-oclusões e métodos relacionados para o tratamento da pele
GB2511941B (en) Compound for use in protecting skin
ZA201507915B (en) Biocide formulation and method for treating water
ZA201505390B (en) Compositions and methods for treating pests
IL245281A0 (en) Methods and preparations for the treatment of cancer
ZA201504175B (en) Biocide composition and method for treating water
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
IL239921A0 (en) Preparations containing solutions in solid state and their use for the treatment of pain
PL2792364T3 (pl) Kompozycja do zapobiegania lub do leczenia kaca
IL244353A0 (en) Compounds and use for cancer treatment
ZA201701426B (en) Compounds for use in anthelminthic treatment
SG11201510300RA (en) Compositions and methods for treating skin
GB201304872D0 (en) Treatment
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
IL243022B (en) Compositions and methods for post-harvest treatment
IL311363A (en) Preparations for use in the treatment of cognitive impairment
GB201311984D0 (en) Methods and compounds for preventing or treating osteoarthritis
GB201307310D0 (en) Treatment
GB201311272D0 (en) Anti-microbial agents and uses thereof
ZA201408732B (en) Composition and methods for treating wounds
GB201302475D0 (en) Compositions and methods for treating biofilms
GB201302474D0 (en) Compositions and methods for treating biofilms